Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

(2020) Courtney D. DiNardo et al.   BLOOD

Molecular MRD status and outcome after transplantation in NPM1-mutated AML

(2020) Richard Dillon et al.   BLOOD

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

(2019) Andrew H. Wei et al.   JOURNAL OF CLINICAL ONCOLOGY

Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD‐driven salvage approach

(2019) Fabio Guolo et al.   BRITISH JOURNAL OF HAEMATOLOGY

Molecular Detection of Minimal Residual Disease before Allogeneic Stem Cell Transplantation Predicts a High Incidence of Early Relapse in Adult Patients with NPM1 Positive Acute Myeloid Leukemia

(2019) Federico Lussana et al.   Cancers

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

(2018) Courtney D. DiNardo et al.   BLOOD

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

(2018) Uwe Platzbecker et al.   LANCET ONCOLOGY

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group

(2017) Marie Balsat et al.   JOURNAL OF CLINICAL ONCOLOGY

Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission

(2016) MICHAL KARAS et al.   ANTICANCER RESEARCH

Assessment of Minimal Residual Disease in Standard-Risk AML

(2016) Adam Ivey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia

(2016) S Kayser et al.   Blood Cancer Journal

The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML

(2013) N. Shayegi et al.   BLOOD

Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group

(2011) Jan Krönke et al.   JOURNAL OF CLINICAL ONCOLOGY